Centerpoint Advisory Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$410K Sell
354
-16
-4% -$18.9K 0.25% 70
2026
Q2
$444K Hold
370
– – 0.28% 68
2026
Q1
$340K Sell
370
-3
-0.8% -$3.04K 0.26% 74
2025
Q4
$401K Hold
373
– – 0.31% 65
2025
Q3
$285K Hold
373
– – 0.22% 79
2025
Q2
$291K Sell
373
-287
-43% -$223K 0.25% 76
2025
Q1
$545K Sell
660
-6
-0.9% -$4.99K 0.54% 49
2024
Q4
$514K Buy
+666
New +$551K 0.5% 51

Other funds holding LLY

Centerpoint Advisory Group's LLY Position: Q3 2026 in Review

Centerpoint Advisory Group reduced its Eli Lilly (LLY) stake by 4.3% in Q3 2026, selling an estimated $18.9K and leaving 354 shares worth $410K. The position accounts for 0.25% of the portfolio, ranked #70.

Centerpoint Advisory Group first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. The position peaked at $545K in Q1 2025. 4,594 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Centerpoint Advisory Group held 354 shares of Eli Lilly worth $410K as of Q3 2026.
  • Centerpoint Advisory Group sold 16 Eli Lilly shares in Q3 2026, an estimated $18.9K.
  • Eli Lilly made up 0.25% of Centerpoint Advisory Group's portfolio in Q3 2026, its #70 holding.
  • Centerpoint Advisory Group first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • Centerpoint Advisory Group's Eli Lilly position peaked at $545K in Q1 2025.
  • 4,594 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Centerpoint Advisory Group's 13F filing for Q3 2026, filed 23 Oct 2026.